000 | 02010 a2200601 4500 | ||
---|---|---|---|
005 | 20250517231532.0 | ||
264 | 0 | _c20190314 | |
008 | 201903s 0 0 eng d | ||
022 | _a1468-3296 | ||
024 | 7 |
_a10.1136/thoraxjnl-2017-211323 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPinder, Emma M | |
245 | 0 | 0 |
_aRandomised controlled trial of GM-CSF in critically ill patients with impaired neutrophil phagocytosis. _h[electronic resource] |
260 |
_bThorax _c10 2018 |
||
300 |
_a918-925 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAged, 80 and over |
650 | 0 | 4 |
_aCritical Illness _xtherapy |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGranulocyte-Macrophage Colony-Stimulating Factor _xadverse effects |
650 | 0 | 4 |
_aHLA-DR Antigens _xmetabolism |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMonocytes _xmetabolism |
650 | 0 | 4 |
_aNeutrophils _xdrug effects |
650 | 0 | 4 |
_aPhagocytosis _xdrug effects |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aRostron, Anthony J | |
700 | 1 | _aHellyer, Thomas P | |
700 | 1 | _aRuchaud-Sparagano, Marie-Helene | |
700 | 1 | _aScott, Jonathan | |
700 | 1 | _aMacfarlane, James G | |
700 | 1 | _aWiscombe, Sarah | |
700 | 1 | _aWiddrington, John D | |
700 | 1 | _aRoy, Alistair I | |
700 | 1 | _aLinnett, Vanessa C | |
700 | 1 | _aBaudouin, Simon V | |
700 | 1 | _aWright, Stephen E | |
700 | 1 | _aChadwick, Thomas | |
700 | 1 | _aFouweather, Tony | |
700 | 1 | _aJuss, Jatinder K | |
700 | 1 | _aChilvers, Edwin R | |
700 | 1 | _aBowett, Susan A | |
700 | 1 | _aParker, Jennie | |
700 | 1 | _aMcAuley, Daniel F | |
700 | 1 | _aConway Morris, Andrew | |
700 | 1 | _aSimpson, A John | |
773 | 0 |
_tThorax _gvol. 73 _gno. 10 _gp. 918-925 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1136/thoraxjnl-2017-211323 _zAvailable from publisher's website |
999 |
_c28688055 _d28688055 |